Genentech, Roche rise on cancer sales

Here's Exhibit Z in the long list of reasons why Big Pharma wants to make deals with biotech--and why speculation about Biogen and Genzyme is running so high. Roche and Genentech are both reaping a big harvest from their joint cancer drugs this quarter.

Genentech's profit skyrocketed by 21 percent on better-than-expected sales of Avastin, which jumped 37 percent to $597 million. Roche's strong cancer-med growth--including its share of Avastin and Herceptin--made up for a shortfall in Tamiflu sales, pushing the company's third-quarter revenues up by 6 percent to $28.7 billion.

- see Genentech's release from Genentech
- check out this news release from Roche
- read the NYT report on Genentech's earnings
- read the article about Roche's results from the International Herald Tribune

Related Articles:
Moody's downgrades pharma industry. Report
Should Pharma take the M&A cure? Report
M&A activity heats up as biotech IPOs struggle. Report
MAbs are hottest segment of biotech industry. Report

Read more on: Genentech | Roche | Avastin

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.